| Literature DB >> 26064949 |
Abstract
Many systems in biology rely on binding of ligands to target proteins in a single high-affinity conformation with a favorable ΔG. Alternatively, interactions of ligands with protein regions that allow diffuse binding, distributed over multiple sites and conformations, can exhibit favorable ΔG because of their higher entropy. Diffuse binding may be biologically important for multidrug transporters and carrier proteins. A fine-grained computational method for numerical integration of total binding ΔG arising from diffuse regional interaction of a ligand in multiple conformations using a Markov Chain Monte Carlo (MCMC) approach is presented. This method yields a metric that quantifies the influence on overall ligand affinity of ligand binding to multiple, distinct sites within a protein binding region. This metric is essentially a measure of dispersion in equilibrium ligand binding and depends on both the number of potential sites of interaction and the distribution of their individual predicted affinities. Analysis of test cases indicates that, for some ligand/protein pairs involving transporters and carrier proteins, diffuse binding contributes greatly to total affinity, whereas in other cases the influence is modest. This approach may be useful for studying situations where "nonspecific" interactions contribute to biological function.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26064949 PMCID: PMC4434174 DOI: 10.1155/2015/746980
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Number of poses in binding site for various ligands. (1) Beta-adrenergic receptor/carazolol (PDB ID: 2rhn_A), a typical tight-binding receptor/ligand complex; (2) AcrB/minocycline (28 heavy atoms); (3) AcrB/acridine orange (20 heavy atoms); and (4) AcrB/toluene (7 heavy atoms).
Relative contributions of multiple poses to predicted affinity.
| Complex | Poses | DBF | EE |
|---|---|---|---|
|
| |||
| AcrB/minocycline | 36 | 5 ± 2 | 2.5 ± 0.8 |
| AcrB/acridine orange | 68 | 14 ± 4 | 6.9 ± 1.2 |
| AcrB/skatole | 1494 | 57 ± 31 | 9.7 ± 5.7 |
| AcrB/toluene | 2429 | 661 ± 139 | 53.7 ± 10.1 |
| OSBP/cholesterol | 10 | 1.3 ± 0.3 | 1.1 ± 0.2 |
| Cinnamomin/ergosterol | 7 | 2.2 ± 1.1 | 1.7 ± 0.4 |
| HSA/diazepam | 5050 | 2298 ± 1703 | 435 ± 333 |
| HSA/halothane | 6897 | 4319 ± 1626 | 1630 ± 695 |
| BAR/carazolol | 3 | 1.8 ± 0.9 | 1.5 ± 0.4 |
|
| |||
| AcrB/minocycline | 52 | 8.5 ± 2.0 | 4.1 ± 1.7 |
| AcrB/acridine orange | 81 | 5.7 ± 3.1 | 3.3 ± 2.3 |
| AcrB/toluene | 1965 | 726 ± 67 | 107 ± 10 |
| AcrB/skatole | 1637 | 526 ± 58 | 76 ± 9 |
Abreviations: OSBP, oxysterol binding protein; HSA, human serum albumin; BAR, beta-adrenergic receptor.
“Poses”, refers to number of possible (P > 0) poses in binding region analyzed.
Analyses performed in triplicate with runs of 100,000 MCMC steps.
Figure 2Toluene binding sites in AcrB. The centroids of the sites are shown. Rotationally equivalent poses may occupy a single site. (a) All pose sites are shown. (b) Sites contributing 52% of total binding are shown. (c) Poses contributing 15% of binding are shown. (d) A single pose contributing 10% of binding is shown. Though a relatively high-affinity site exists, low-affinity sites make up the bulk of binding probability.
Figure 3Specific versus nonspecific binding. The number of steps per pose is plotted versus the number of poses with a specific number of steps. A high value on the vertical axis indicates many low-affinity poses. A high value on the horizontal axis indicates a few high-affinity poses. Triangles, AcrB/toluene; squares, AcrB/acridine orange; diamonds, AcrB/minocycline. The graph for skatole was nearly identical to the line for toluene except for a single higher affinity site and is omitted for clarity. See text for details.